Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

212 results about "Heavy-chain antibody" patented technology

A heavy-chain antibody is an antibody which consists only of two heavy chains and lacks the two light chains usually found in antibodies. In common antibodies, the antigen binding region consists of the variable domains of the heavy and light chains (VH and VL). Heavy-chain antibodies can bind antigens despite having only VH domains. This observation has led to the development of a new type of antibody fragments with potential use as drugs, so-called single-domain antibodies.

Aflatoxin nano antibody gene pool, construction method and application of aflatoxin nano antibody gene pool as well as aflatoxin B1 nano antibody 2014AFB-G15

The invention relates to an aflatoxin nano antibody gene pool, a construction method and application of the aflatoxin nano antibody gene pool as well as an aflatoxin B1 nano antibody 2014AFB-G15. The aflatoxin nano antibody gene pool is prepared by extracting RNA (ribonucleic acid) in alpaca blood after immunization of an aflatoxin B1 antigen, performing specific amplification on a variable region gene of an alpaca heavy chain antibody by adopting an RT-PCR (reverse transcription-polymerase chain reaction) method to obtain an aflatoxin nano antibody VHH gene, and then performing transformation after connecting with a pCANTAB5E (his) vector. The aflatoxin B1 nano antibody 2014AFB-G15 obtained by screening, disclosed by the invention, has the characteristics of organic reagent resistance, high temperature resistance and the like, and is good in stability; the IC50 (half maximal inhibitory concentration) of the aflatoxin B1 nano antibody 2014AFB-G15 to the aflatoxin B1 is 0.66ng / mL, and the cross reactivity of the aflatoxin B1 nano antibody 2014AFB-G15 to the aflatoxins B2, G1,G2 and M1 is 22.6%, 0.95%, 32.1% and 26% respectively.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI

Nano-antibody GN1 specifically combined with GPC3 protein and preparation method and application thereof

The invention relates to the technical field of biology, in particular to a nano-antibody GN1 specifically combined with a GPC3 protein. The nano-antibody GN1 is composed of a variable region of a heavy-chain antibody, the variable region of the heavy-chain antibody comprises an antigenic determinant complementary region and a skeleton region, the skeleton region is selected from the group consisting of FR1, FR2, FR3 and FR4 and homologous sequences thereof, the antigenic determinant complementary region is selected from the group consisting of CDR1, CDR2 and CDR3 and homologous sequences thereof, the amino acid sequences of the CDR1 to the CDR3 are shown in the formulas of SEQ ID NO. 1 to SEQ ID NO. 3, the amino acid sequences of the FR1-4 are shown in formulas of SEQ ID NO. 4-7, the amino acid sequence of the antibody is shown in the formula of SEQ ID NO.8, and the nucleotide sequence for encoding the amino acid is shown in the formula of SEQ ID NO.9. The nano-antibody GN1 can be specifically combined with hepatoma carcinoma cells highly expressing the GPC3 protein to inhibit hepatoma carcinoma cell proliferation. The amino acid sequence of the nano-antibody GN1 or the nucleotidesequence of the nano-antibody GN1 or the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 or the recombinant cell containing the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 can be applied to research and development of diagnostic reagents and drugs for treating liver cancer.
Owner:GUANGXI UNIVERSITY OF TECHNOLOGY

Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes. Methods of determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL that is susceptible to treatment directed to eliminating idiotype specific B cell receptor-bearing B-CLL cells are also provided, as are methods of following the progression of treatment of B-CLL in the patient. Additionally, methods of treating a patient having B-CLL are provided, as are methods of identifying a therapeutic agent for B-CLL.
Owner:THE FEINSTEIN INST FOR MEDICAL RES

Nanobody GN2 composed of variable region of heavy chain antibody and preparation method and application of nanobody GN2

The present invention relates to a nanobody GN2 composed of a variable region of a heavy chain antibody; and the variable region of the heavy chain antibody comprises an epitope complementary region selected from a group consisting of CDR1, CDR2 and CDR3 and homologous sequences of the CDR1, CDR2 and CDR3 and a skeleton region selected from a group consisting of FR1, FR2, FR3 and FR4 and homologous sequences of the FR1, FR2, FR3 and FR4. The present invention also relates to a preparation method and an application of the nanobody GN2. The nanobody GN2 can specifically bind to hepatocarcinoma cells that highly express GPC3 protein, inhibits hepatocarcinoma cell proliferation, and is small in molecular weight, stable in structure, good in heat resistance, high in affinity, easy for storage and transportation, weak in immunogenicity to human body, also strong in tumor tissue penetrating power, liable to express and genetically engineered, and particularly suitable for use as a diagnosticreagent or a therapeutic antibody. The method can retain more antigen epitopes, and is high in carrier quality, good in an enzyme digestion effect, high in connection efficiency, low in self-connection efficiency and also low in cost.
Owner:GUANGXI UNIVERSITY OF TECHNOLOGY

Binding molecules

The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions.The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.
Owner:HARBOUR ANTIBODIES BV +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products